Literature DB >> 25103110

The microRNA-15 family inhibits the TGFβ-pathway in the heart.

Anke J Tijsen1, Ingeborg van der Made1, Maarten M van den Hoogenhof1, Wino J Wijnen1, Elza D van Deel2, Nina E de Groot1, Sergey Alekseev1, Kees Fluiter3, Blanche Schroen4, Marie-José Goumans5, Jolanda van der Velden6, Dirk J Duncker2, Yigal M Pinto1, Esther E Creemers7.   

Abstract

AIMS: The overloaded heart remodels by cardiomyocyte hypertrophy and interstitial fibrosis, which contributes to the development of heart failure. Signalling via the TGFβ-pathway is crucial for this remodelling. Here we tested the hypothesis that microRNAs in the overloaded heart regulate this remodelling process via inhibition of the TGFβ-pathway. METHODS AND
RESULTS: We show that the miRNA-15 family, which we found to be up-regulated in the overloaded heart in multiple species, inhibits the TGFβ-pathway by targeting of TGFBR1 and several other genes within this pathway directly or indirectly, including p38, SMAD3, SMAD7, and endoglin. Inhibition of miR-15b by subcutaneous injections of LNA-based antimiRs in C57BL/6 mice subjected to transverse aorta constriction aggravated fibrosis and to a lesser extent also hypertrophy.
CONCLUSION: We identified the miR-15 family as a novel regulator of cardiac hypertrophy and fibrosis acting by inhibition of the TGFβ-pathway. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Fibrosis; Hypertrophy; TGFβ-pathway; miRNA-15 family

Mesh:

Substances:

Year:  2014        PMID: 25103110     DOI: 10.1093/cvr/cvu184

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  65 in total

Review 1.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

Review 2.  MicroRNAs in cardiovascular ageing.

Authors:  Timon Seeger; Reinier A Boon
Journal:  J Physiol       Date:  2015-07-05       Impact factor: 5.182

Review 3.  Connecting sex differences, estrogen signaling, and microRNAs in cardiac fibrosis.

Authors:  Lejla Medzikovic; Laila Aryan; Mansoureh Eghbali
Journal:  J Mol Med (Berl)       Date:  2019-08-26       Impact factor: 4.599

Review 4.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

Review 5.  Circadian MicroRNAs in Cardioprotection.

Authors:  Yoshimasa Oyama; Colleen Marie Bartman; Jennifer Gile; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 6.  MicroRNA: A new therapeutic strategy for cardiovascular diseases.

Authors:  Saheli Samanta; Sathyamoorthy Balasubramanian; Sheeja Rajasingh; Urmi Patel; Anuradha Dhanasekaran; Buddhadeb Dawn; Johnson Rajasingh
Journal:  Trends Cardiovasc Med       Date:  2016-03-03       Impact factor: 6.677

Review 7.  Biomarkers for the identification of cardiac fibroblast and myofibroblast cells.

Authors:  Emiri Tarbit; Indu Singh; Jason N Peart; Roselyn B Rose'Meyer
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

8.  MicroRNA-98 inhibits TGF-β1-induced differentiation and collagen production of cardiac fibroblasts by targeting TGFBR1.

Authors:  Ranran Cheng; Ruiying Dang; Yan Zhou; Min Ding; Huikun Hua
Journal:  Hum Cell       Date:  2017-03-01       Impact factor: 4.174

9.  YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF.

Authors:  Yingzhun Chen; Xiaoguang Zhao; Jian Sun; Wei Su; Lu Zhang; Yingnan Li; Yingqi Liu; Lijia Zhang; Yanjie Lu; Hongli Shan; Haihai Liang
Journal:  Cell Death Differ       Date:  2019-01-15       Impact factor: 15.828

Review 10.  Novel Biological Therapies Targeting Heart Failure: Myocardial Rejuvenation.

Authors:  Amanda J Favreau-Lessard; Sergey Ryzhov; Douglas B Sawyer
Journal:  Heart Fail Clin       Date:  2016-05-10       Impact factor: 3.179

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.